Publication Date:
2022
Short description:
Radium-223 in mCPRC patients: a large real-life Italian multicenter study / Frantellizzi, V., Monari, F., Mascia, M., Costa, R.P., Rubini, G., Spanu, A., Farcomeni, A., Lodi Rizzini, E., Cindolo, L., Tripoli, V., Lavelli, V., Nuvoli, S., Pontico, M., Dionisi, V., Ferrari, C., De Vincentis, G.. - In: MINERVA UROLOGY AND NEPHROLOGY. - ISSN 2724-6442. - Volume 74, Issue 1, Pages 21 - 28 February 2022:(2022). [10.23736/S2724-6051.20.03808-4]
abstract:
Radium-223 is a targeted alpha-particles therapy approved for the treatment of mCRPC patients with symptomatic bone metastases. To our knowledge we account for the largest cohort of mCRPC patients subjected to Radium-223 treatment in our country. We aim to describe in a real-life setting the largest cohort of mCRPC patients treated with Radium-223 ever taken into consideration.
Iris type:
1.1 Articolo in rivista
List of contributors:
Frantellizzi, Viviana; Monari, Fabio; Mascia, Manlio; Costa, Renato P; Rubini, Giuseppe; Spanu, Angela; Farcomeni, Alessio; Lodi Rizzini, Elisa; Cindolo, Luca; Tripoli, Vincenzo; Lavelli, Valentina; Nuvoli, Susanna; Pontico, Mariano; Dionisi, Valeria; Ferrari, Cristina; De Vincentis, Giuseppe
Published in: